Skip to main content

HCPCS Level II

HCPCS Level II 2006 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2006, grouped by effective date. Each code's own page carries its full record.

376
Added
0
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2006 (308)

  • A0998 — Ambulance response and treatment, no transport
  • A4218 — Sterile saline or water, metered dose dispenser, 10 ml
  • A4233 — Replacement battery, alkaline (other than j cell), for use with medically necessary home blood glucose monitor owned by patient, each
  • A4234 — Replacement battery, alkaline, j cell, for use with medically necessary home blood glucose monitor owned by patient, each
  • A4235 — Replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each
  • A4236 — Replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each
  • A4363 — Ostomy clamp, any type, replacement only, each
  • A4411 — Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, with built-in convexity, each
  • A4412 — Ostomy pouch, drainable, high output, for use on a barrier with flange (2 piece system), without filter, each
  • A4604 — Tubing with integrated heating element for use with positive airway pressure device
  • A5120 — Skin barrier, wipes or swabs, each
  • A5512 — For diabetics only, multiple density insert, direct formed, molded to foot after external heat source of 230 degrees fahrenheit or higher, total contact with patient's foot, including arch, base layer minimum of 1/4 inch material of shore a 35 durometer or 3/16 inch material of shore a 40 durometer (or higher), prefabricated, each
  • A5513 — For diabetics only, multiple density insert, custom molded from model of patient's foot, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each
  • A6457 — Tubular dressing with or without elastic, any width, per linear yard
  • A6513 — Compression burn mask, face and/or neck, plastic or equal, custom fabricated
  • A6530 — Gradient compression stocking, below knee, 18-30 mmhg, each
  • A6531 — Gradient compression stocking, below knee, 30-40 mmhg, used as a surgical dressing, each
  • A6532 — Gradient compression stocking, below knee, 40-50 mmhg, used as a surgical dressing, each
  • A6533 — Gradient compression stocking, thigh length, 18-30 mmhg, each
  • A6534 — Gradient compression stocking, thigh length, 30-40 mmhg, each
  • A6535 — Gradient compression stocking, thigh length, 40 mmhg or greater, each
  • A6536 — Gradient compression stocking, full length/chap style, 18-30 mmhg, each
  • A6537 — Gradient compression stocking, full length/chap style, 30-40 mmhg, each
  • A6538 — Gradient compression stocking, full length/chap style, 40 mmhg or greater, each
  • A6539 — Gradient compression stocking, waist length, 18-30 mmhg, each
  • A6540 — Gradient compression stocking, waist length, 30-40 mmhg, each
  • A6541 — Gradient compression stocking, waist length, 40 mmhg or greater, each
  • A6544 — Gradient compression stocking, garter belt
  • A6549 — Gradient compression garment, not otherwise specified, for daytime use, each
  • A9275 — Home glucose disposable monitor, includes test strips
  • A9281 — Reaching/grabbing device, any type, any length, each
  • A9282 — Wig, any type, each
  • A9536 — Technetium tc-99m depreotide, diagnostic, per study dose, up to 35 millicuries
  • A9537 — Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries
  • A9538 — Technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries
  • A9539 — Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries
  • A9540 — Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries
  • A9541 — Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries
  • A9542 — Indium in-111 ibritumomab tiuxetan, diagnostic, per study dose, up to 5 millicuries
  • A9543 — Yttrium y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries
  • A9544 — Iodine i-131 tositumomab, diagnostic, per study dose
  • A9545 — Iodine i-131 tositumomab, therapeutic, per treatment dose
  • A9546 — Cobalt co-57/58, cyanocobalamin, diagnostic, per study dose, up to 1 microcurie
  • A9547 — Indium in-111 oxyquinoline, diagnostic, per 0.5 millicurie
  • A9548 — Indium in-111 pentetate, diagnostic, per 0.5 millicurie
  • A9550 — Technetium tc-99m sodium gluceptate, diagnostic, per study dose, up to 25 millicurie
  • A9551 — Technetium tc-99m succimer, diagnostic, per study dose, up to 10 millicuries
  • A9552 — Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
  • A9553 — Chromium cr-51 sodium chromate, diagnostic, per study dose, up to 250 microcuries
  • A9554 — Iodine i-125 sodium iothalamate, diagnostic, per study dose, up to 10 microcuries
  • A9555 — Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries
  • A9556 — Gallium ga-67 citrate, diagnostic, per millicurie
  • A9557 — Technetium tc-99m bicisate, diagnostic, per study dose, up to 25 millicuries
  • A9558 — Xenon xe-133 gas, diagnostic, per 10 millicuries
  • A9559 — Cobalt co-57 cyanocobalamin, oral, diagnostic, per study dose, up to 1 microcurie
  • A9560 — Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries
  • A9561 — Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries
  • A9562 — Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries
  • A9563 — Sodium phosphate p-32, therapeutic, per millicurie
  • A9564 — Chromic phosphate p-32 suspension, therapeutic, per millicurie
  • A9566 — Technetium tc-99m fanolesomab, diagnostic, per study dose, up to 25 millicuries
  • A9567 — Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries
  • A9698 — Non-radioactive contrast imaging material, not otherwise classified, per study
  • B4185 — Parenteral nutrition solution, not otherwise specified, 10 grams lipids
  • C1820 — Generator, neurostimulator (implantable), with rechargeable battery and charging system
  • C8957 — Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump
  • C9726 — Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure
  • E0170 — Commode chair with integrated seat lift mechanism, electric, any type
  • E0171 — Commode chair with integrated seat lift mechanism, non-electric, any type
  • E0172 — Seat lift mechanism placed over or on top of toilet, any type
  • E0485 — Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, prefabricated, includes fitting and adjustment
  • E0486 — Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
  • E0641 — Standing frame/table system, multi-position (e.g., three-way stander), any size including pediatric, with or without wheels
  • E0642 — Standing frame/table system, mobile (dynamic stander), any size including pediatric
  • E0705 — Transfer device, any type, each
  • E0762 — Transcutaneous electrical joint stimulation device system, includes all accessories
  • E0764 — Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program
  • E0911 — Trapeze bar, heavy duty, for patient weight capacity greater than 250 pounds, attached to bed, with grab bar
  • E0912 — Trapeze bar, heavy duty, for patient weight capacity greater than 250 pounds, free standing, complete with grab bar
  • E1392 — Portable oxygen concentrator, rental
  • E1812 — Dynamic knee, extension/flexion device with active resistance control
  • E2207 — Wheelchair accessory, crutch and cane holder, each
  • E2208 — Wheelchair accessory, cylinder tank carrier, each
  • E2209 — Accessory, arm trough, with or without hand support, each
  • E2210 — Wheelchair accessory, bearings, any type, replacement only, each
  • E2211 — Manual wheelchair accessory, pneumatic propulsion tire, any size, each
  • E2212 — Manual wheelchair accessory, tube for pneumatic propulsion tire, any size, each
  • E2213 — Manual wheelchair accessory, insert for pneumatic propulsion tire (removable), any type, any size, each
  • E2214 — Manual wheelchair accessory, pneumatic caster tire, any size, each
  • E2215 — Manual wheelchair accessory, tube for pneumatic caster tire, any size, each
  • E2216 — Manual wheelchair accessory, foam filled propulsion tire, any size, each
  • E2217 — Manual wheelchair accessory, foam filled caster tire, any size, each
  • E2218 — Manual wheelchair accessory, foam propulsion tire, any size, each
  • E2219 — Manual wheelchair accessory, foam caster tire, any size, each
  • E2220 — Manual wheelchair accessory, solid (rubber/plastic) propulsion tire, any size, replacement only, each
  • E2221 — Manual wheelchair accessory, solid (rubber/plastic) caster tire (removable), any size, replacement only, each
  • E2222 — Manual wheelchair accessory, solid (rubber/plastic) caster tire with integrated wheel, any size, replacement only, each
  • E2224 — Manual wheelchair accessory, propulsion wheel excludes tire, any size, replacement only, each
  • E2225 — Manual wheelchair accessory, caster wheel excludes tire, any size, replacement only, each
  • E2226 — Manual wheelchair accessory, caster fork, any size, replacement only, each
  • E2371 — Power wheelchair accessory, group 27 sealed lead acid battery, (e.g., gel cell, absorbed glassmat), each
  • E2372 — Power wheelchair accessory, group 27 non-sealed lead acid battery, each
  • G0235 — Pet imaging, any site, not otherwise specified
  • G0333 — Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary
  • G0378 — Hospital observation service, per hour
  • G0379 — Direct admission of patient for hospital observation care
  • G8126 — Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
  • G8127 — Patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
  • G8128 — Clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure
  • G9050 — Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
  • G9051 — Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed therapy or managing consequences of cancer directed therapy (for use in a medicare-approved demonstration project)
  • G9052 — Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent disease; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
  • G9053 — Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
  • G9054 — Oncology; primary focus of visit; supervising, coordinating or managing care of patient with terminal cancer or for whom other medical illness prevents further cancer treatment; includes symptom management, end-of-life care planning, management of palliative therapies (for use in a medicare-approved demonstration project)
  • G9055 — Oncology; primary focus of visit; other, unspecified service not otherwise listed (for use in a medicare-approved demonstration project)
  • G9056 — Oncology; practice guidelines; management adheres to guidelines (for use in a medicare-approved demonstration project)
  • G9057 — Oncology; practice guidelines; management differs from guidelines as a result of patient enrollment in an institutional review board approved clinical trial (for use in a medicare-approved demonstration project)
  • G9058 — Oncology; practice guidelines; management differs from guidelines because the treating physician disagrees with guideline recommendations (for use in a medicare-approved demonstration project)
  • G9059 — Oncology; practice guidelines; management differs from guidelines because the patient, after being offered treatment consistent with guidelines, has opted for alternative treatment or management, including no treatment (for use in a medicare-approved demonstration project)
  • G9060 — Oncology; practice guidelines; management differs from guidelines for reason(s) associated with patient comorbid illness or performance status not factored into guidelines (for use in a medicare-approved demonstration project)
  • G9061 — Oncology; practice guidelines; patient's condition not addressed by available guidelines (for use in a medicare-approved demonstration project)
  • G9062 — Oncology; practice guidelines; management differs from guidelines for other reason(s) not listed (for use in a medicare-approved demonstration project)
  • G9063 — Oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage i (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9064 — Oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage ii (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9065 — Oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage iii a (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9066 — Oncology; disease status; limited to non-small cell lung cancer; stage iii b- iv at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9067 — Oncology; disease status; limited to non-small cell lung cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9068 — Oncology; disease status; limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9069 — Oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/non-small cell; extensive stage at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9070 — Oncology; disease status; small cell lung cancer, limited to small cell and combined small cell/non-small; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9071 — Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i or stage iia-iib; or t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9072 — Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage i, or stage iia-iib; or t3, n1, m0; and er and pr negative; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9073 — Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage iiia-iiib; and not t3, n1, m0; and er and/or pr positive; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9074 — Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; stage iiia-iiib; and not t3, n1, m0; and er and pr negative; with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9075 — Oncology; disease status; invasive female breast cancer (does not include ductal carcinoma in situ); adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9077 — Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t1-t2c and gleason 2-7 and psa < or equal to 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9078 — Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t2 or t3a gleason 8-10 or psa > 20 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9079 — Oncology; disease status; prostate cancer, limited to adenocarcinoma as predominant cell type; t3b-t4, any n; any t, n1 at diagnosis with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9080 — Oncology; disease status; prostate cancer, limited to adenocarcinoma; after initial treatment with rising psa or failure of psa decline (for use in a medicare-approved demonstration project)
  • G9083 — Oncology; disease status; prostate cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9084 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n0, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9085 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t4, n0, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9086 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-4, n1-2, m0 with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9087 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive with current clinical, radiologic, or biochemical evidence of disease (for use in a medicare-approved demonstration project)
  • G9088 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive without current clinical, radiologic, or biochemical evidence of disease (for use in a medicare-approved demonstration project)
  • G9089 — Oncology; disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9090 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-2, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9091 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t3, n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9092 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t1-3, n1-2, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence or metastases (for use in a medicare-approved demonstration project)
  • G9093 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease initially established as t4, any n, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9094 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9095 — Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9096 — Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as t1-t3, n0-n1 or nx (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9097 — Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease initially established as t4, any n, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9098 — Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9099 — Oncology; disease status; esophageal cancer, limited to adenocarcinoma or squamous cell carcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9100 — Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post r0 resection (with or without neoadjuvant therapy) with no evidence of disease recurrence, progression, or metastases (for use in a medicare-approved demonstration project)
  • G9101 — Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; post r1 or r2 resection (with or without neoadjuvant therapy) with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
  • G9102 — Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic m0, unresectable with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
  • G9103 — Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9104 — Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9105 — Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9106 — Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; post r1 or r2 resection with no evidence of disease progression, or metastases (for use in a medicare-approved demonstration project)
  • G9107 — Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; unresectable at diagnosis, m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9108 — Oncology; disease status; pancreatic cancer, limited to adenocarcinoma; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9109 — Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as t1-t2 and n0, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9110 — Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease initially established as t3-4 and/or n1-3, m0 (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9111 — Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a medicare-approved demonstration project)
  • G9112 — Oncology; disease status; head and neck cancer, limited to cancers of oral cavity, pharynx and larynx with squamous cell as predominant cell type; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9113 — Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage ia-b (grade 1) without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9114 — Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage ia-b (grade 2-3); or stage ic (all grades); or stage ii; without evidence of disease progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9115 — Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage iii-iv; without evidence of progression, recurrence, or metastases (for use in a medicare-approved demonstration project)
  • G9116 — Oncology; disease status; ovarian cancer, limited to epithelial cancer; evidence of disease progression, or recurrence, and/or platinum resistance (for use in a medicare-approved demonstration project)
  • G9117 — Oncology; disease status; ovarian cancer, limited to epithelial cancer; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • G9123 — Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; chronic phase not in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
  • G9124 — Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; accelerated phase not in hematologic cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
  • G9125 — Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; blast phase not in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
  • G9126 — Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
  • G9128 — Oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)
  • G9129 — Oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)
  • G9130 — Oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, staging in progress, or not listed (for use in a medicare-approved demonstration project)
  • J0132 — Injection, acetylcysteine, 100 mg
  • J0133 — Injection, acyclovir, 5 mg
  • J0278 — Injection, amikacin sulfate, 100 mg
  • J0365 — Injection, aprotonin, 10,000 kiu
  • J0480 — Injection, basiliximab, 20 mg
  • J0795 — Injection, corticorelin ovine triflutate, 1 microgram
  • J0881 — Injection, darbepoetin alfa, 1 microgram (non-esrd use)
  • J0882 — Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
  • J0885 — Injection, epoetin alfa, (for non-esrd use), 1000 units
  • J0886 — Injection, epoetin alfa, 1000 units (for esrd on dialysis)
  • J1162 — Injection, digoxin immune fab (ovine), per vial
  • J1265 — Injection, dopamine hcl, 40 mg
  • J1430 — Injection, ethanolamine oleate, 100 mg
  • J1451 — Injection, fomepizole, 15 mg
  • J1566 — Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
  • J1640 — Injection, hemin, 1 mg
  • J1675 — Injection, histrelin acetate, 10 micrograms
  • J1945 — Injection, lepirudin, 50 mg
  • J2278 — Injection, ziconotide, 1 microgram
  • J2325 — Injection, nesiritide, 0.1 mg
  • J2425 — Injection, palifermin, 50 micrograms
  • J2503 — Injection, pegaptanib sodium, 0.3 mg
  • J2504 — Injection, pegademase bovine, 25 iu
  • J2513 — Injection, pentastarch, 10% solution, 100 ml
  • J2805 — Injection, sincalide, 5 micrograms
  • J2850 — Injection, secretin, synthetic, human, 1 microgram
  • J3285 — Injection, treprostinil, 1 mg
  • J3355 — Injection, urofollitropin, 75 iu
  • J3471 — Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)
  • J3472 — Injection, hyaluronidase, ovine, preservative free, per 1000 usp units
  • J7189 — Factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram
  • J7306 — Levonorgestrel (contraceptive) implant system, including implants and supplies
  • J7620 — Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme
  • J7627 — Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg
  • J7640 — Formoterol, inhalation solution, compounded product, administered through dme, unit dose form, 12 micrograms
  • J8498 — Antiemetic drug, rectal/suppository, not otherwise specified
  • J8515 — Cabergoline, oral, 0.25 mg
  • J8540 — Dexamethasone, oral, 0.25 mg
  • J8597 — Antiemetic drug, oral, not otherwise specified
  • J9025 — Injection, azacitidine, 1 mg
  • J9027 — Injection, clofarabine, 1 mg
  • J9175 — Injection, elliotts' b solution, 1 ml
  • J9225 — Histrelin implant (vantas), 50 mg
  • J9264 — Injection, paclitaxel protein-bound particles, 1 mg
  • L0491 — Tlso, sagittal-coronal control, modular segmented spinal system, two rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal and coronal planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
  • L0492 — Tlso, sagittal-coronal control, modular segmented spinal system, three rigid plastic shells, posterior extends from the sacrococcygeal junction and terminates just inferior to the scapular spine, anterior extends from the symphysis pubis to the xiphoid, soft liner, restricts gross trunk motion in the sagittal and coronal planes, lateral strength is provided by overlapping plastic and stabilizing closures, includes straps and closures, prefabricated, includes fitting and adjustment
  • L0621 — Sacroiliac orthosis, flexible, provides pelvic-sacral support, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, prefabricated, off-the-shelf
  • L0622 — Sacroiliac orthosis, flexible, provides pelvic-sacral support, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, custom fabricated
  • L0623 — Sacroiliac orthosis, provides pelvic-sacral support, with rigid or semi-rigid panels over the sacrum and abdomen, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, prefabricated, off-the-shelf
  • L0624 — Sacroiliac orthosis, provides pelvic-sacral support, with rigid or semi-rigid panels placed over the sacrum and abdomen, reduces motion about the sacroiliac joint, includes straps, closures, may include pendulous abdomen design, custom fabricated
  • L0625 — Lumbar orthosis, flexible, provides lumbar support, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include pendulous abdomen design, shoulder straps, stays, prefabricated, off-the-shelf
  • L0626 — Lumbar orthosis, sagittal control, with rigid posterior panel(s), posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0627 — Lumbar orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from l-1 to below l-5 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0628 — Lumbar-sacral orthosis, flexible, provides lumbo-sacral support, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include stays, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf
  • L0629 — Lumbar-sacral orthosis, flexible, provides lumbo-sacral support, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include stays, shoulder straps, pendulous abdomen design, custom fabricated
  • L0630 — Lumbar-sacral orthosis, sagittal control, with rigid posterior panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0631 — Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0632 — Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, custom fabricated
  • L0633 — Lumbar-sacral orthosis, sagittal-coronal control, with rigid posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0634 — Lumbar-sacral orthosis, sagittal-coronal control, with rigid posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, stays, shoulder straps, pendulous abdomen design, custom fabricated
  • L0635 — Lumbar-sacral orthosis, sagittal-coronal control, lumbar flexion, rigid posterior frame/panel(s), lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, prefabricated, includes fitting and adjustment
  • L0636 — Lumbar sacral orthosis, sagittal-coronal control, lumbar flexion, rigid posterior frame/panels, lateral articulating design to flex the lumbar spine, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, anterior panel, pendulous abdomen design, custom fabricated
  • L0637 — Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0638 — Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, custom fabricated
  • L0639 — Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
  • L0640 — Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, custom fabricated
  • L0859 — Addition to halo procedure, magnetic resonance image compatible systems, rings and pins, any material
  • L2034 — Knee ankle foot orthosis, full plastic, single upright, with or without free motion knee, medial lateral rotation control, with or without free motion ankle, custom fabricated
  • L2387 — Addition to lower extremity, polycentric knee joint, for custom fabricated knee ankle foot orthosis, each joint
  • L3671 — Shoulder orthosis, shoulder joint design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3702 — Elbow orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3763 — Elbow wrist hand orthosis, rigid, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3764 — Elbow wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3765 — Elbow wrist hand finger orthosis, rigid, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3766 — Elbow wrist hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3905 — Wrist hand orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3913 — Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3919 — Hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3921 — Hand finger orthosis, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3933 — Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment
  • L3935 — Finger orthosis, nontorsion joint, may include soft interface, custom fabricated, includes fitting and adjustment
  • L3961 — Shoulder elbow wrist hand orthosis, shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3967 — Shoulder elbow wrist hand orthosis, abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3971 — Shoulder elbow wrist hand orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3973 — Shoulder elbow wrist hand orthosis, abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3975 — Shoulder elbow wrist hand finger orthosis, shoulder cap design, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3976 — Shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3977 — Shoulder elbow wrist hand finger orthosis, shoulder cap design, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L3978 — Shoulder elbow wrist hand finger orthosis, abduction positioning (airplane design), thoracic component and support bar, includes one or more nontorsion joints, elastic bands, turnbuckles, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L5703 — Ankle, symes, molded to patient model, socket without solid ankle cushion heel (sach) foot, replacement only
  • L5858 — Addition to lower extremity prosthesis, endoskeletal knee shin system, microprocessor control feature, stance phase only, includes electronic sensor(s), any type
  • L5971 — All lower extremity prosthesis, solid ankle cushion heel (sach) foot, replacement only
  • L6621 — Upper extremity prosthesis addition, flexion/extension wrist with or without friction, for use with external powered terminal device
  • L6677 — Upper extremity addition, harness, triple control, simultaneous operation of terminal device and elbow
  • L6883 — Replacement socket, below elbow/wrist disarticulation, molded to patient model, for use with or without external power
  • L6884 — Replacement socket, above elbow/elbow disarticulation, molded to patient model, for use with or without external power
  • L6885 — Replacement socket, shoulder disarticulation/interscapular thoracic, molded to patient model, for use with or without external power
  • L7400 — Addition to upper extremity prosthesis, below elbow/wrist disarticulation, ultralight material (titanium, carbon fiber or equal)
  • L7401 — Addition to upper extremity prosthesis, above elbow disarticulation, ultralight material (titanium, carbon fiber or equal)
  • L7402 — Addition to upper extremity prosthesis, shoulder disarticulation/interscapular thoracic, ultralight material (titanium, carbon fiber or equal)
  • L7403 — Addition to upper extremity prosthesis, below elbow/wrist disarticulation, acrylic material
  • L7404 — Addition to upper extremity prosthesis, above elbow disarticulation, acrylic material
  • L7405 — Addition to upper extremity prosthesis, shoulder disarticulation/interscapular thoracic, acrylic material
  • L7600 — Prosthetic donning sleeve, any material, each
  • L8609 — Artificial cornea
  • L8623 — Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each
  • L8624 — Lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor, ear level, replacement, each
  • L8680 — Implantable neurostimulator electrode, each
  • L8681 — Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
  • L8682 — Implantable neurostimulator radiofrequency receiver
  • L8683 — Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
  • L8684 — Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement
  • L8685 — Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
  • L8686 — Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
  • L8687 — Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
  • L8688 — Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
  • L8689 — External recharging system for battery (internal) for use with implantable neurostimulator, replacement only
  • Q0510 — Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
  • Q0511 — Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
  • Q0512 — Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
  • Q0513 — Pharmacy dispensing fee for inhalation drug(s); per 30 days
  • Q0514 — Pharmacy dispensing fee for inhalation drug(s); per 90 days
  • Q0515 — Injection, sermorelin acetate, 1 microgram
  • S2068 — Breast reconstruction with deep inferior epigastric perforator (diep) flap or superficial inferior epigastric artery (siea) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral
  • S2079 — Laparoscopic esophagomyotomy (heller type)
  • S3854 — Gene expression profiling panel for use in the management of breast cancer treatment
  • V2788 — Presbyopia correcting function of intraocular lens

Added effective July 1, 2006 (1)

  • K0733 — Power wheelchair accessory, 12 to 24 amp hour sealed lead acid battery, each (e.g., gel cell, absorbed glassmat)

Added effective October 1, 2006 (67)

  • C9727 — Insertion of implants into the soft palate; minimum of three implants
  • K0738 — Portable gaseous oxygen system, rental; home compressor used to fill portable oxygen cylinders; includes portable containers, regulator, flowmeter, humidifier, cannula or mask, and tubing
  • K0800 — Power operated vehicle, group 1 standard, patient weight capacity up to and including 300 pounds
  • K0801 — Power operated vehicle, group 1 heavy duty, patient weight capacity 301 to 450 pounds
  • K0802 — Power operated vehicle, group 1 very heavy duty, patient weight capacity 451 to 600 pounds
  • K0806 — Power operated vehicle, group 2 standard, patient weight capacity up to and including 300 pounds
  • K0807 — Power operated vehicle, group 2 heavy duty, patient weight capacity 301 to 450 pounds
  • K0808 — Power operated vehicle, group 2 very heavy duty, patient weight capacity 451 to 600 pounds
  • K0812 — Power operated vehicle, not otherwise classified
  • K0813 — Power wheelchair, group 1 standard, portable, sling/solid seat and back, patient weight capacity up to and including 300 pounds
  • K0814 — Power wheelchair, group 1 standard, portable, captains chair, patient weight capacity up to and including 300 pounds
  • K0815 — Power wheelchair, group 1 standard, sling/solid seat and back, patient weight capacity up to and including 300 pounds
  • K0816 — Power wheelchair, group 1 standard, captains chair, patient weight capacity up to and including 300 pounds
  • K0820 — Power wheelchair, group 2 standard, portable, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0821 — Power wheelchair, group 2 standard, portable, captains chair, patient weight capacity up to and including 300 pounds
  • K0822 — Power wheelchair, group 2 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0823 — Power wheelchair, group 2 standard, captains chair, patient weight capacity up to and including 300 pounds
  • K0824 — Power wheelchair, group 2 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0825 — Power wheelchair, group 2 heavy duty, captains chair, patient weight capacity 301 to 450 pounds
  • K0826 — Power wheelchair, group 2 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0827 — Power wheelchair, group 2 very heavy duty, captains chair, patient weight capacity 451 to 600 pounds
  • K0828 — Power wheelchair, group 2 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more
  • K0829 — Power wheelchair, group 2 extra heavy duty, captains chair, patient weight 601 pounds or more
  • K0830 — Power wheelchair, group 2 standard, seat elevator, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0831 — Power wheelchair, group 2 standard, seat elevator, captains chair, patient weight capacity up to and including 300 pounds
  • K0835 — Power wheelchair, group 2 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0836 — Power wheelchair, group 2 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
  • K0837 — Power wheelchair, group 2 heavy duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0838 — Power wheelchair, group 2 heavy duty, single power option, captains chair, patient weight capacity 301 to 450 pounds
  • K0839 — Power wheelchair, group 2 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0840 — Power wheelchair, group 2 extra heavy duty, single power option, sling/solid seat/back, patient weight capacity 601 pounds or more
  • K0841 — Power wheelchair, group 2 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0842 — Power wheelchair, group 2 standard, multiple power option, captains chair, patient weight capacity up to and including 300 pounds
  • K0843 — Power wheelchair, group 2 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0848 — Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0849 — Power wheelchair, group 3 standard, captains chair, patient weight capacity up to and including 300 pounds
  • K0850 — Power wheelchair, group 3 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0851 — Power wheelchair, group 3 heavy duty, captains chair, patient weight capacity 301 to 450 pounds
  • K0852 — Power wheelchair, group 3 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0853 — Power wheelchair, group 3 very heavy duty, captains chair, patient weight capacity 451 to 600 pounds
  • K0854 — Power wheelchair, group 3 extra heavy duty, sling/solid seat/back, patient weight capacity 601 pounds or more
  • K0855 — Power wheelchair, group 3 extra heavy duty, captains chair, patient weight capacity 601 pounds or more
  • K0856 — Power wheelchair, group 3 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0857 — Power wheelchair, group 3 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
  • K0858 — Power wheelchair, group 3 heavy duty, single power option, sling/solid seat/back, patient weight 301 to 450 pounds
  • K0859 — Power wheelchair, group 3 heavy duty, single power option, captains chair, patient weight capacity 301 to 450 pounds
  • K0860 — Power wheelchair, group 3 very heavy duty, single power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0861 — Power wheelchair, group 3 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0862 — Power wheelchair, group 3 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0863 — Power wheelchair, group 3 very heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0864 — Power wheelchair, group 3 extra heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 601 pounds or more
  • K0868 — Power wheelchair, group 4 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0869 — Power wheelchair, group 4 standard, captains chair, patient weight capacity up to and including 300 pounds
  • K0870 — Power wheelchair, group 4 heavy duty, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0871 — Power wheelchair, group 4 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds
  • K0877 — Power wheelchair, group 4 standard, single power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0878 — Power wheelchair, group 4 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds
  • K0879 — Power wheelchair, group 4 heavy duty, single power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0880 — Power wheelchair, group 4 very heavy duty, single power option, sling/solid seat/back, patient weight 451 to 600 pounds
  • K0884 — Power wheelchair, group 4 standard, multiple power option, sling/solid seat/back, patient weight capacity up to and including 300 pounds
  • K0885 — Power wheelchair, group 4 standard, multiple power option, captains chair, patient weight capacity up to and including 300 pounds
  • K0886 — Power wheelchair, group 4 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds
  • K0890 — Power wheelchair, group 5 pediatric, single power option, sling/solid seat/back, patient weight capacity up to and including 125 pounds
  • K0891 — Power wheelchair, group 5 pediatric, multiple power option, sling/solid seat/back, patient weight capacity up to and including 125 pounds
  • K0898 — Power wheelchair, not otherwise classified
  • K0899 — Power mobility device, not coded by dme pdac or does not meet criteria
  • S2325 — Hip core decompression

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2006
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger